...
首页> 外文期刊>Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry >Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine.
【24h】

Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine.

机译:糖尿病引起的视网膜硝化压力,并通过氨基胍进行校正。

获取原文
获取原文并翻译 | 示例

摘要

Aminoguanidine inhibits the development of retinopathy in diabetic animals, but the mechanism remains unclear. Inasmuch as aminoguanidine is a relatively selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), we have investigated the effects of hyperglycemia on the retinal nitric oxide (NO) pathway in the presence and absence of aminoguanidine. In vivo studies utilized retinas from experimentally diabetic rats treated or without aminoguanidine for 2 months, and in vitro studies used bovine retinal endothelial cells and a transformed retinal glial cell line (rMC-1) incubated in 5 mm and 25 mm glucose with and without aminoguanidine (100 microg/mL). NO was detected as nitrite and nitrate, and nitrotyrosine and iNOS were detected using immunochemical methods. Retinal homogenates from diabetic animals had greater than normal levels of NO and iNOS (p < 0.05), and nitrotyrosine was greater than normal, especially in one band immunoprecipitated from retinal homogenates. Oral aminoguanidine significantly inhibited all of these increases. Nitrotyrosine was detected immunohistochemically only in the retinal vasculature of non-diabetic and diabetic animals. Retinal endothelial and rMC-1 cells cultured in high glucose increased NO and NT, and aminoguanidine inhibited both increases in rMC-1 cells, but only NT in endothelial cells. Hyperglycemia increases NO production in retinal cells, and aminoguanidine can inhibit this abnormality. Inhibition of diabetic retinopathy by aminoguanidine might be mediated in part by inhibition of sequelae of NO production.
机译:氨基胍可抑制糖尿病动物视网膜病变的发展,但机制尚不清楚。由于氨基胍是一氧化氮合酶(iNOS)诱导型亚型的相对选择性抑制剂,因此我们研究了在存在和不存在氨基胍的情况下高血糖对视网膜一氧化氮(NO)途径的影响。体内研究利用了接受或未应用氨基胍治疗的实验性糖尿病大鼠视网膜的视网膜长达2个月,而体外研究则使用了在5毫米和25毫米葡萄糖中(有或没有氨基胍)孵育的牛视网膜内皮细胞和转化的视网膜胶质细胞系(rMC-1) (100微克/毫升)。使用免疫化学方法检测到亚硝酸盐和硝酸盐中的NO,以及硝酸酪氨酸和iNOS。糖尿病动物的视网膜匀浆的NO和iNOS水平高于正常水平(p <0.05),硝基酪氨酸也高于正常水平,尤其是在从视网膜匀浆免疫沉淀的一条带中。口服氨基胍显着抑制了所有这些增加。仅在非糖尿病和糖尿病动物的视网膜脉管系统中免疫组化检测到了硝基酪氨酸。在高葡萄糖中培养的视网膜内皮细胞和rMC-1细胞增加了NO和NT,而氨基胍抑制了rMC-1细胞中的这两种增加,但在内皮细胞中仅抑制了NT。高血糖会增加视网膜细胞中NO的产生,而氨基胍可以抑制这种异常。氨基胍对糖尿病性视网膜病的抑制作用可能部分由抑制NO产生的后遗症介导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号